首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   4776篇
  免费   213篇
  国内免费   59篇
耳鼻咽喉   27篇
儿科学   55篇
妇产科学   36篇
基础医学   574篇
口腔科学   57篇
临床医学   262篇
内科学   1236篇
皮肤病学   43篇
神经病学   396篇
特种医学   329篇
外科学   966篇
综合类   30篇
预防医学   168篇
眼科学   30篇
药学   276篇
中国医学   9篇
肿瘤学   554篇
  2023年   36篇
  2022年   26篇
  2021年   91篇
  2020年   53篇
  2019年   90篇
  2018年   94篇
  2017年   105篇
  2016年   100篇
  2015年   103篇
  2014年   146篇
  2013年   145篇
  2012年   272篇
  2011年   297篇
  2010年   198篇
  2009年   154篇
  2008年   283篇
  2007年   323篇
  2006年   321篇
  2005年   311篇
  2004年   304篇
  2003年   304篇
  2002年   322篇
  2001年   73篇
  2000年   62篇
  1999年   69篇
  1998年   51篇
  1997年   54篇
  1996年   47篇
  1995年   57篇
  1994年   55篇
  1993年   70篇
  1992年   51篇
  1991年   55篇
  1990年   34篇
  1989年   33篇
  1988年   28篇
  1987年   23篇
  1986年   14篇
  1985年   20篇
  1984年   37篇
  1983年   17篇
  1982年   14篇
  1981年   24篇
  1980年   14篇
  1979年   11篇
  1978年   8篇
  1977年   8篇
  1976年   6篇
  1974年   5篇
  1971年   5篇
排序方式: 共有5048条查询结果,搜索用时 31 毫秒
1.
Stones in the common bile duct (CBD) are reported worldwide, and this condition is majorly managed through endoscopic retrograde cholangiopancreatography (ERCP). CBD stone recurrence is an important issue after endoscopic stone removal. Therefore, it is essential to identify its risk factors to determine the necessity of regular follow-up in patients who underwent endoscopic removal of CBD stones. The authors identified that the S and polyline morphological subtypes of CBD were associated with increased stone recurrence. New morphological subtypes of CBD presented by the authors can be important risk predictors of recurrence after endoscopic stone removal. Furthermore, the new morphological subtypes of CBD may predict the risk of residual CBD stones or technical difficulty in CBD stone removal. Further studies with a large sample size and longer follow-up durations are warranted to examine the usefulness of the newly identified morphological subtypes of CBD in predicting the outcomes of ERCP for CBD stone removal.  相似文献   
2.
3.
4.
5.
Cyclin‐dependent kinase 12 (CDK12), one of the key factors associated with DNA damage response pathways, is located on chromosome 17 proximal to Erb‐B2 receptor tyrosine kinase 2 (ERBB2). In this report, CDK12 and ERBB2 coamplification was detected by targeted next‐generation sequencing in two urothelial carcinomas. The staining intensity of the CDK12 and human epidermal growth factor receptor‐2 proteins was associated with the prognosis of each urothelial carcinoma case. Our results suggest that CDK12 coamplification with ERBB2 might be associated with tumor aggressiveness and contribution to cancer pathogenesis. Therapies targeting CDK12 should be developed for these patients.  相似文献   
6.
7.
8.
9.
10.
PurposePrevious studies have reported different methods of estrogen administration during endometrial preparation for frozen‐thawed embryo transfer (FET). This study aimed to investigate a beneficial regimen of transdermal estrogen administration for FET.MethodsWe investigated the reproductive and obstetric outcomes of FET by comparing the increasing dose (ID) group that mimics changes in serum estradiol during the menstrual cycle and the constant dose (CD) group. Transdermal patches were used for estrogen administration in both groups. In our hospital, we targeted 315 cycles of the ID group in which FET was performed in 2017 and 324 cycles of the CD group in which FET was performed in 2018. In all cases, single embryo transfer was performed.ResultsAll were singleton pregnancies. There was no difference in clinical pregnancy rate (28.9% vs 28.2%, P =.837) and live birth rate (17.3% vs 21.4%, P =.201) between the ID and CD groups. Spontaneous abortion rate was significantly lower in the CD group than in the ID group (37.2% vs 23.0%, P =.041). There was no difference in obstetrical outcomes.ConclusionsIt was considered that the simple CD regimen may be more beneficial than the complicated ID regimen.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号